Pravastatin sodium

2 years -80 in solvent

Orally

Pravastatin is in Phase IV clinical trial of patients with Hyperlipidemia.

sterile water

Pravastatin-Na at 10 uM inhibits the sterol synthesis at a level greater than 50% in PBMC. [1] Pravastatin produces relaxation of isolated aortic rings, with maximum vasorelaxations of 62.8% at 10 uM and latency of ca.8 min. Pravastatin (< 10 uM) stimulates NOS activity and NO release within 10 min in cultured bovine aortic endothelial cells. L-arginine potentiates NO production in response to Pravastatin (< 10 uM) in cultured bovine aortic endothelial cells. [2] Pravastatin results in a dose-dependent inhibition of macrophage cholesterol synthesis in human monocyte derived macrophages(HMDM), mouse peritoneal macrophages (MPM) and a J-774 A.1 macrophagelike cell lines. Small concentrations of pravastatin (< 0.19 ug/mL) increases the cellular cholesterol esterification rate after incubation with LDL, but higher concentrations (< 100 ug/mL) results in an inhibition of the esterification. [3] Pravastatin (< 0.5 mM) decreases Rho/ROCK pathway activity in human colon and ileum explants, which leads to decreased CCN2 mRNA levels. Pravastatin (<1 mM) also induces CCN2 inhibition in primary human smooth muscle cells. Pravastatin (< 0.5 mM) decreases type I collagen and fibronectin mRNA levels in both human colon and ileum explants and primary human smooth muscle cells. [4]

DMSO 89 mg/mL, Water 89 mg/mL, Ethanol 12 mg/mL

sodium (3R, 5R)-3, 5-dihydroxy-7-((1S, 2S, 6S, 8S, 8aR)-6-hydroxy-2-methyl-8-((S)-2-methylbutanoyloxy)-1, 2, 6, 7, 8, 8a-hexahydronaphthalen-1-yl)heptanoate